- Merck KGaA offers $20 per ADS for Silence Therapeutics
- Total deal value $1.3 billion
- Offer price more than double Friday's close
Merck KGaA agreed to acquire Silence Therapeutics for $1.3 billion, offering $20 per ADS, more than double Friday's close. The deal adds divesiran, an experimental drug for polycythemia vera, to Merck's pipeline.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.